Abstract
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have